Hematology billing services for infusion and procedure groups

The hematology codes we bill most

Modifiers that matter

Payer rules to know

Top denials in hematology billing services for infusion and procedure groups

What does hematology billing cover?

Benign hematology billing covers the visits, procedures, blood products and drugs used to treat anemia, clotting disorders and blood disease that is not cancer. The work splits into four lines: bone marrow procedures, infusions and injections, transfusions and phlebotomy, and the drugs themselves. Chemotherapy administration belongs to oncology billing, and we do not repeat it here.

The place of service decides which claim form carries what. A hematologist who infuses iron in the office files a CMS-1500 for the visit, the administration code and the drug. In a hospital outpatient department the hospital files a UB-04 for the drug and administration.

Visit coding for anemia work-ups and anticoagulation follow-up is on our internal medicine billing page.

Which codes should a hematology billing team know best?

Three facts from the CMS files cause most of the errors.

First, the October 2026 CMS fee schedule file (RVU26D) gives 36430, 96365 and 99195 a PC/TC indicator of 5. CMS defines that as an incident-to code and says payment may not be made by the Part B MAC when the service is given to hospital inpatients or outpatients. The same file marks the facility column "NA" for these codes, so the physician claim is an office claim.

Second, 38220, 38221 and 38222 have a PC/TC indicator of 0 and a global period of XXX, so modifiers 26 and TC do not apply. Third, 36000 carries status B (bundled), matching the NCCI rule that vein access is not billed when an infusion or transfusion needs it.

How do we bill bone marrow aspiration and biopsy?

Report 38222 when the aspiration and the biopsy are done on the same iliac bone at the same visit. Report 38220 alone for an aspiration only and 38221 alone for a biopsy only. The 2026 NCCI Medicare Policy Manual (chapter V, section E) says 38220 and 38221 may be reported together only when the two procedures are done on different iliac bones or the sternum, or at separate patient encounters.

Modifier 59 is the common mistake. NCCI chapter I allows it on the 38221 and 38220 pair only for separate sites or encounters, and not when both are done on the same iliac bone, which is the usual practice. That case is 38222.

Chapter X of the NCCI manual says the aspirate smear interpretation is 85097, and a cell block or a marrow biopsy core is read with 88305. When one specimen is submitted, only one surgical pathology code is reported. The technical and professional splits are on our pathology billing page.

NCCI also says 38220 may not be reported with spinal fusion, laminectomy and similar procedures, or for aspirate used in platelet-rich injections.

How do we bill iron infusions?

Bill the iron product on its HCPCS Level II code with the units the descriptor sets, plus one administration code. The October 2026 HCPCS file lists iron sucrose as J1756 (1 mg), iron dextran as J1750 (50 mg), sodium ferric gluconate as J2916 (12.5 mg), ferric carboxymaltose as J1439 (1 mg), ferric derisomaltose as J1437 (10 mg) and ferumoxytol for non-ESRD use as Q0138 (1 mg). A 500 mg dose is 500 units of J1439 but 50 units of J1437.

The administration code is usually 96365 (infusion) or 96374 (push). NCCI chapter XI allows one initial service code per encounter unless a second access site is medically necessary, and says placing a peripheral IV (36000, 36410) and saline used to carry the drug or keep the line open are not billed. A same-day visit needs modifier 25 and its own separately identifiable work.

Coverage is where iron claims differ from other infusions. The national coverage determination (NCD) 110.10 covers sodium ferric gluconate and iron sucrose only for hemodialysis patients who also receive erythropoietin. Outside that group, coverage is set by the LCD of your MAC, so you read the policy for your jurisdiction and its diagnosis list before scheduling.

Plans steer to preferred products. UnitedHealthcare's commercial policy 2026D0088R (effective September 1, 2026) requires, for Injectafer, records supporting iron deficiency anemia, oral iron failure or a listed exception, and lab values showing failure of at least two of Feraheme, Ferrlecit, Infed or Venofer, drawn 4 to 12 weeks after the last course. Its Medicare Advantage step therapy policy (effective January 1, 2026) lists those four as preferred and Injectafer and Monoferric as non-preferred.

The diagnosis must match the labs. The FY2027 ICD-10-CM set has D50.0 (iron deficiency anemia secondary to chronic blood loss), D50.9 (unspecified) and D63.1 (anemia in chronic kidney disease).

What do ESA claims need for Medicare?

An ESA, an erythropoiesis-stimulating agent such as epoetin alfa or darbepoetin alfa, needs a modifier and a recent hemoglobin or hematocrit on every Medicare claim. Chapter 17 of the Claims Processing Manual, section 80.9, requires one of EA (chemotherapy-induced anemia), EB (radiotherapy-induced) or EC (neither) on non-ESRD claims for J0881 and J0885. Institutional claims without it are returned, and professional claims are returned as unprocessable.

Section 80.8 requires the most recent hemoglobin or hematocrit on every ESA claim. Institutional claims carry value code 48 (hemoglobin) or 49 (hematocrit). Professional paper claims use item 19 of the CMS-1500, and electronic claims use the Loop 2400 MEA segment with MEA02 set to R1 for hemoglobin or R2 for hematocrit. A missing value is rejected with CARC 16 and RARC N764.

Only one ESA modifier is allowed per line, so different reasons go on separate lines, such as J0881EA and J0881EC. The 2026 HCPCS file lists J0882 and J0886 for dialysis patients and J0881 and J0885 for non-ESRD use. For chronic renal failure patients not yet on dialysis, section 80.10 has hospitals report ESA charges under revenue code 0636.

The coverage limits come from NCD 110.21. For anemia from myelosuppressive chemotherapy, Medicare covers an ESA only when hemoglobin is under 10 g/dL (or hematocrit under 30%) before treatment or maintenance, and continued use is not reasonable and necessary if hemoglobin rises less than 1 g/dL from baseline after 8 weeks. The NCD names non-covered uses such as anemia from iron or B-12 deficiency, bleeding or hemolysis, and prophylactic use, and section 80.12 denies EC lines carrying those diagnoses.

How do we bill transfusions in a clinic or hospital outpatient department?

A hospital outpatient department reports the transfusion CPT code under revenue code 0391 (blood administration). The Claims Processing Manual, chapter 4, section 231.8, says transfusion services are billed per service, not per unit, and that a blood product HCPCS code is needed for payment.

The same section says a transfusion APC is paid once per day, whatever the number of units or products, so the P-code lines carry the units. Under section 231.1, when the hospital pays only processing and storage, those charges go under revenue code 0390, 0392 or 0399 with the blood HCPCS code, the units and the date of service.

When the hospital also pays for the blood itself, section 231.2 requires two lines with the same date, units and HCPCS code, both with modifier BL: one under revenue code series 038X and one for processing and storage. Packed red cells use revenue code 0381 and whole blood 0382 so the blood deductible applies.

NCCI chapter X says a P-code for an irradiated, CMV-negative, deglycerolized, pooled or frozen product already includes irradiation (86945), CMV antibody testing, freezing, thawing and pooling. NCCI chapter XI adds that the peripheral IV start and line-patency fluid are included.

Because 36430 carries PC/TC indicator 5, a Part B MAC does not pay it for hospital outpatients. NCD 110.7 treats a medically necessary transfusion as generally covered under Parts A and B, and NCD 110.8 covers platelet transfusion when reasonable and necessary.

How do we bill therapeutic phlebotomy?

Therapeutic phlebotomy is 99195, used when blood is removed as treatment, for example for polycythemia vera (D45) or hereditary hemochromatosis (E83.110). The 2026 CMS file gives it PC/TC indicator 5 and marks the facility column NA, so it is an office service.

NCCI chapter XI says 99195 cannot be reported with autologous blood collection (86890, 86891), plasmapheresis or exchange transfusion, and that services built into the phlebotomy, including 36000, 36410 and 96360 to 96379, are not billed. Document the order, volume removed and triggering lab value.

How do we bill anticoagulation management?

Anticoagulation management of a patient on warfarin is 93793, and the 2026 CMS file gives it PC/TC indicator 2 and marks the facility column NA. Z79.01 (long term current use of anticoagulants) supports the claim.

Home INR monitoring has its own HCPCS codes and a national policy. NCD 190.11 covers home PT/INR monitoring for patients on warfarin with mechanical heart valves, chronic atrial fibrillation or venous thromboembolism, but only after at least 3 months of anticoagulation and a face-to-face education session, and testing no more often than once a week. The HCPCS file has G0248 (demonstration), G0249 (test materials) and G0250 (physician review), the last two with four tests per unit.

How do sickle cell and hemophilia claims differ?

Sickle cell claims are infusion and visit claims with specific diagnoses; hemophilia claims are drug claims priced per international unit. The FY2027 ICD-10-CM set separates crisis from non-crisis: D57.00 is Hb-SS disease with crisis, unspecified, D57.01 adds acute chest syndrome, D57.1 is sickle-cell disease without crisis and D57.3 is sickle-cell trait.

NCCI chapter XI allows hydration (96360, 96361) when medically necessary, such as correcting dehydration, but not when it runs concurrently with another drug administration. Crizanlizumab is J0791 (5 mg), and the one-time gene therapies are J3392 (exagamglogene autotemcel) and J3394 (lovotibeglogene autotemcel), each per treatment. CMS's Cell and Gene Therapy Access Model covers Medicaid outcomes-based agreements for sickle cell gene therapy in participating states, with standardized prior authorization.

Hemophilia factor is billed on a J code per international unit, for example J7190 (factor VIII, human, per I.U.) and J7192 (factor VIII recombinant, not otherwise specified). Chapter 17, section 80.4, prices clotting factor not paid on a cost or prospective basis as a drug at ASP plus 6 percent. Section 80.4.1 lists the clotting factor furnishing fee at $0.265 per unit for 2026, and says CMS builds it into the published payment limit for the factor code.

Setting changes payment. Section 80.4 says factor given to a hemophilia inpatient in a covered Part A stay at a PPS hospital is paid in addition to the DRG, and OPPS hospitals are paid the APC when factor is billed under Part B.

How do wastage modifiers apply to hematology drugs?

Use JW for the discarded part of a single-dose vial and JZ when nothing was discarded, on separately payable Part B drugs. Chapter 17, section 40, puts the administered amount on one line with no modifier and the discarded amount on a second line with JW. The full rules are on our oncology billing page.

Iron is billed per 1 mg or 12.5 mg, so a partial vial usually produces a JW line with units in the descriptor amount. Section 40 excludes multiple-dose containers, so the label decides whether JW or JZ applies at all.

Which hematology drugs need prior authorization?

It depends on the payer and the plan year, and there is no single list. Commercial and Medicare Advantage plans publish their own drug policies. The UnitedHealthcare iron policies above show the pattern: records, step-therapy history and lab values before a non-preferred product is covered.

We check the payer's current drug policy at scheduling and file the request before the first dose, as described on our prior authorization page. A missing authorization comes back as CARC 197.

What are the most common hematology denials?

We work every denial within 48 hours. Bundled-line denials (CARC 97) are often self-inflicted: a vein access code billed with an infusion, or 38220 with 38221 on the same bone.

Medical necessity denials (CARC 50) need the lab values: hemoglobin, ferritin, transferrin saturation or INR with the date drawn. A step-therapy denial is a coverage rule, not a coding error, so the appeal shows the prior products tried. Our denial management team builds it from the record.

How do we handle hematology billing?

We code from the procedure note, infusion record and transfusion log, then check each claim against the NCCI manual and the payer's drug policy. Claims are sent within 24 hours of charge entry, and denials are worked within 48 hours.

For hospitals we prepare the UB-04 side, including revenue codes for blood and drugs, and for groups the professional claim on the CMS-1500, inside your EHR. To see how this would work for your hematology service, book a call.